* Targeting therapy for patients with genetic mutations through the MyDrug study (75)* For example: inhibition of the IL-6/JAK/STAT3 pathway overexpressed on MM cells in FHRMM* For example: PD-1 or TIGIT inhibition given their overexpression on exhausted T cells in FHRMM. This evidence concerns the gene STAT3 and Miyoshi myopathy.